Klinické štúdie Obézita v štáte Arizona
40 štúdií pre Obézita hľadá účastníkov v zariadeniach v štáte Arizona.
Mestá v štáte Arizona
- Phoenix22 štúdií
- Tucson17 štúdií
- Scottsdale6 štúdií
- Chandler5 štúdií
- Peoria4 štúdií
- Gilbert4 štúdií
- Mesa3 štúdií
Oficiálny text štúdie (anglicky)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Headlands Research - Scottsdale /ID# 282571, Scottsdale
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT07752979A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Pima Heart, Tucson
- Eclipse Clinical Research, Tucson
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07783802Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- AMR Clinical, Tempe
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07837973Early Tracking of Childhood Health Determinants (ETCHED) Study
- NIDDK, Phoenix, Phoenix
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
1 Day – 99 Years · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT03481829A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- University of Arizona, Tucson
Prebieha náborFáza 3
Vek 6 až 17 · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06672549A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Tucson Clinical Research Institute, Tucson
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07282600A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- RIO Clinical Trials - Phoenix, Phoenix
- Headlands Research - Scottsdale, Scottsdale
- Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Mesa
- Research Site, Phoenix
- Research Site, Tucson
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Synexus Clinical Research US, Inc., Phoenix
- Medical Advancement Centers of Arizona, Phoenix
Prebieha náborFáza 3
Vek 45 až 99 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Headlands Research - Scottsdale, Scottsdale
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07321886Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Care Access - 801 South Power Road, Mesa, Mesa
- Elite Pain and Spine Institute - South Crimson Road, Mesa
- Elite Clinical Studies, LLC, Phoenix
- a 1 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07353931A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler
- Headlands Research - Scottsdale, Scottsdale
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07589608Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NIDDK, Phoenix, Phoenix
Prebieha náborVítaní zdravých dobrovoľníkov
Vek 18 až 99 · Všetky pohlavia · Aktualizované 21. 9. 2026 · NCT06223555A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Phoenix
- AURORA-1 Clinical Site, Tucson
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Peoria
- AURORA-2 Clinical Site, Phoenix
- AURORA-2 Clinical Site, Tucson
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- HonorHealth, Phoenix
- Medical Advancement Centers of Arizona, Phoenix
- Pima Heart and Vascular Clinical Research, Tucson
- a 1 ďalších
Prebieha náborFáza 3
Vek 18 až 99 · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Arizona Clinical Trials, Tucson
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Helios Clinical Research - Phoenix, Phoenix
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT06897475A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Arizona Clinical Trials, Tucson
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Chandler
- ACCOMPLISH-2 Research Site, Phoenix
- ACCOMPLISH-2 Research Site, Sun City West
- a 1 ďalších
Prebieha náborFáza 3Vítaní zdravých dobrovoľníkov
Vek 18 až 79 · Všetky pohlavia · Aktualizované 11. 9. 2026 · NCT07654374AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Dignity Health, Mercy Gilbert, Gilbert
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT07571109A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler
- Headlands Research - Scottsdale, Scottsdale
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT06143956A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, Gilbert
- Synexus Clinical Research US, Inc., Phoenix
- Pima Heart, Tucson
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT07215559A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Medical Dermatology Specialists, Phoenix
Prebieha náborFáza 4
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Phoenix
- Kailera Clinical Site, Sun City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT07284901Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Sun City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Gilbert Center for Family Medicine, Gilbert
Prebieha náborFáza 3
Vek 18 až 99 · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT07684144Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Glendale
- Kailera Clinical Site, Phoenix
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 9. 2026 · NCT07284979The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure
- NIDDK, Phoenix, Phoenix
Prebieha náborVítaní zdravých dobrovoľníkov
Vek 18 až 60 · Všetky pohlavia · Aktualizované 28. 8. 2026 · NCT05545306Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Arizona Clinical Trials, Chandler
- Epic Medical Research - Sun City, Sun City
Prebieha náborFáza 3
Vek 18 až 99 · Všetky pohlavia · Aktualizované 27. 8. 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Mesa
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT07784725Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
- Exponent Phoenix, Phoenix
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 8. 2026 · NCT07776678A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Mercy Gilbert Medical Center, Gilbert
- Sun City Clinical Research, Glendale
- Honor Health, Phoenix
- a 1 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 8. 2026 · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Phoenix
- ACCOMPLISH-1 Research Site, Sun City West
- ACCOMPLISH-1 Research Site, Tucson
Prebieha náborFáza 3
Vek 18 až 79 · Všetky pohlavia · Aktualizované 10. 8. 2026 · NCT07654361Fibrosis Lessens After Metabolic Surgery
- Banner Health Center, Phoenix
Prebieha náborFáza 4Vítaní zdravých dobrovoľníkov
Vek 18 až 75 · Všetky pohlavia · Aktualizované 31. 7. 2026 · NCT06374875A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Arizona Research Center, Inc., Phoenix
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 7. 2026 · NCT07481630A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
- Arizona Liver Health, Chandler
- Adobe Clinical Research, Tucson
Prebieha náborFáza 1/2
Vek 18 až 65 · Všetky pohlavia · Aktualizované 8. 7. 2026 · NCT06836609Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
- Mayo Clinic in Arizona, Scottsdale
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Vek 30 až 70 · Všetky pohlavia · Aktualizované 28. 1. 2026 · NCT04232566Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
- The University of Arizona College of Medicine- Phoenix, Phoenix
Prebieha náborFáza 3
Vek 18 až 75 · Všetky pohlavia · Aktualizované 14. 11. 2025 · NCT06499857A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- PRANDIAL Lab, Flagstaff
Prebieha náborVítaní zdravých dobrovoľníkov
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 11. 2024 · NCT04755062Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.